The disordered protein SERF promotes α-Synuclein aggregation through liquid–liquid phase separation
Journal of Biological Chemistry · 2024
DOI: 10.1016/j.jbc.2024.105667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von He-Ning Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. Hauptthemen laut MEDLINE: alpha-Synuclein, Parkinson Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Beijing University of Chemical Technology, National Key Research and Development Program of China.
Abstract (Originalsprache)
The aggregation of α-Synuclein (α-Syn) into amyloid fibrils is the hallmark of Parkinson's disease. Under stress or other pathological conditions, the accumulation of α-Syn oligomers is the main contributor to the cytotoxicity. A potential approach for treating Parkinson's disease involves preventing the accumulation of these α-Syn oligomers. In this study, we present a novel mechanism involving a conserved group of disorderly proteins known as small EDRK-rich factor (SERF), which promotes the aggregation of α-Syn through a cophase separation process. Using diverse methods like confocal microscopy, fluorescence recovery after photobleaching assays, solution-state NMR spectroscopy, and Western blot, we determined that the N-terminal domain of SERF1a plays a role in the interactions that occur during cophase separation. Within these droplets, α-Syn undergoes a gradual transformation from solid condensates to amyloid fibrils, while SERF1a is excluded from the condensates and dissolves into the solution. Notably, in vivo experiments show that SERF1a cophase separation with α-Syn significantly reduces the deposition of α-Syn oligomers and decreases its cellular toxicity under stress. These findings suggest that SERF1a accelerates the conversion of α-Syn from highly toxic oligomers to less toxic fibrils through cophase separation, thereby mitigating the biological damage of α-Syn aggregation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
- Key Lab of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, China.
- Department of Biology, Shenzhen MSU-BIT University, Shenzhen, China. Electronic address: xyshi@smbu.edu.cn.
- Key Lab of Bioorganic Phosphorus Chemistry & Chemical Biology, Department of Chemistry, Tsinghua University, Beijing, China. Electronic address: liym@mail.tsinghua.edu.cn.
- Beijing Key Laboratory of Bioprocess, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China. Electronic address: luosz@mail.buct.edu.cn.
Förderung
- National Natural Science Foundation of China
- Beijing University of Chemical Technology
- National Key Research and Development Program of China
Zitieren
APA
Liu, H. N., Wang, T., Hu, J. J., Chen, L., Shi, X., Li, Y. M., & Luo, S. Z. (2024). The disordered protein SERF promotes α-Synuclein aggregation through liquid–liquid phase separation. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2024.105667
Vancouver
Liu HN, Wang T, Hu JJ, Chen L, Shi X, Li YM, et al. The disordered protein SERF promotes α-Synuclein aggregation through liquid–liquid phase separation. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2024.105667
BibTeX
@article{Liu2024,
author = {Liu, He-Ning and Wang, Ting and Hu, Jin-Jian and Chen, Long and Shi, Xiangyan and Li, Yan-Mei and Luo, Shi-Zhong},
title = {The disordered protein SERF promotes α-Synuclein aggregation through liquid–liquid phase separation},
journal = {Journal of Biological Chemistry},
year = {2024},
doi = {10.1016/j.jbc.2024.105667}
}
EUVIMED